SuperworthcbdMD EPS YCBD
Diluted earnings per share by quarter and over the last twelve months, from 2016.
- Last 12 months, to Sep 30, 2024
- n/m
- a quarter missing
- Latest quarter, Q4 FY24
- −$1.44
- Fiscal year 2024
- n/a
cbdMD's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q4 FY24, it was −$1.44.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | n/a | n/a |
| FY2023 | −$184.64 | n/a |
| FY2022 | −$450.88 | n/a |
| FY2021 | −$172.80 | −166% |
| FY2020 | $262.80 | n/a |
| FY2018 | −$25.20 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY24 | −$1.44 | n/a | n/a | |
| Q3 FY24 | −$1.20 | n/a | n/a | |
| Q2 FY24 | −$10.80 | n/a | n/a | |
| Q4 FY23 | −$132.64 | n/a | −$184.64 | |
| Q3 FY23 | −$9.28 | n/a | −$143.84 | |
| Q2 FY23 | −$13.92 | n/a | −$333.04 | |
| Q1 FY23 | −$28.80 | n/a | −$353.68 | |
| Q4 FY22 | −$91.84 | n/a | −$450.88 | |
| Q3 FY22 | −$198.48 | −2857% | −$387.84 | |
| Q2 FY22 | −$34.56 | n/a | −$182.16 | |
| Q1 FY22 | −$126.00 | n/a | −$234.00 | |
| Q4 FY21 | −$28.80 | n/a | −$172.80 |
Against its peers
Companies in Consumer Defensive nearest cbdMD's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| YCBDcbdMD | n/m | |
| EDUCEducational Development | $0.19 | |
| JVACoffee | $0.83 | +159% a year |
| RAVERave Restaurant | $0.21 | +11% a year |
| AXILAxil Brands | $0.34 | +127% a year |
| Peer median | $0.28 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on cbdMD
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.